[Potential pro-thrombotic effects of cyclooxygenase-2. inhibitors Two cases pf myocardial infarction].
Type 2 cyclo-oxygenase inhibitors are new anti-inflammatory drugs with better gastrointestinal tolerance than traditional non-steroidal anti-inflammatory drugs. They have no platelet anti-aggregant effects and there is still some discussion as to whether this new therapeutic class has any pro-thrombotic effects. The authors report two cases of myocardial infarction in patients considered to be at low risk treated by type 2 cyclo-oxygenase inhibitors.
Thuaire
C
C
Service de cardiologie CHG Louis Pasteur 28018 Chartres Le Coudray.
Mankoubi
L
L
Rangé
G
G
Roussel
L
L
Belfaqih
H
H
el Khayef
L
L
Belghit
A
A
Charaf
M
M
Albert
F
F
D000328:Adult; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005165:Factor V / Q000235:genetics; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D009154:Mutation; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000235:genetics; D011451:Prostaglandin-Endoperoxide Synthases; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome; D016277:Ventricular Function, Left
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; C095381:factor V Leiden; D005165:Factor V; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D010959:Tissue Plasminogen Activator